| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
39,760,000 |
| Market
Cap: |
191.25(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.23 - $7.4 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Puma Biotechnology is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. Co. in-licenses from Pfizer, Inc., the global development and commercialization rights to PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Co. is primarily focused on the development and commercialization of the oral version of neratinib, and its drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
86,405 |
323,302 |
557,781 |
| Total Sell Value |
$0 |
$387,400 |
$1,175,528 |
$1,897,450 |
| Total People Sold |
0 |
5 |
11 |
11 |
| Total Sell Transactions |
0 |
6 |
19 |
55 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gross Phillip |
10% Owner |
– – • |
2017-06-02 |
4 |
S |
$83.06 |
$2,531,287 |
I/I |
(30,475) |
4,250,968 |
|
- |
|
| Gross Phillip |
10% Owner |
– – • |
2017-06-01 |
4 |
S |
$83.55 |
$434,436 |
I/I |
(5,200) |
4,281,443 |
|
- |
|
| Gross Phillip |
10% Owner |
– – • |
2017-06-01 |
4 |
S |
$82.41 |
$13,542,220 |
I/I |
(164,325) |
4,286,643 |
|
- |
|
| Eyler Charles R |
SEE REMARKS |
• – – |
2017-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
30,680 |
|
- |
|
| Gross Phillip |
10% Owner |
– – • |
2017-05-26 |
4 |
S |
$76.72 |
$23,121,263 |
I/I |
(300,000) |
4,450,968 |
|
- |
|
| Gross Phillip |
10% Owner |
– – • |
2017-05-25 |
4 |
S |
$76.91 |
$31,146,560 |
I/I |
(400,000) |
4,750,968 |
|
- |
|
| Gross Phillip |
10% Owner |
– – • |
2017-05-24 |
4 |
S |
$69.00 |
$35,469,990 |
I/I |
(485,700) |
5,150,968 |
|
- |
|
| Gross Phillip |
10% Owner |
– – • |
2017-05-24 |
4 |
S |
$68.13 |
$3,406,455 |
I/I |
(50,000) |
5,636,668 |
|
- |
|
| Charnas Robert |
See Remarks |
– – – |
2017-02-01 |
4 |
AS |
$31.80 |
$95,755 |
D/D |
(3,008) |
26,453 |
|
- |
|
| Lo Steven |
Chief Commercial Officer |
• – – |
2017-01-20 |
4 |
AS |
$33.24 |
$76,108 |
D/D |
(2,290) |
29,210 |
|
- |
|
| Eyler Charles R |
SEE REMARKS |
• – – |
2017-01-20 |
4 |
AS |
$33.24 |
$27,253 |
D/D |
(820) |
9,680 |
|
- |
|
| Charnas Robert |
See Remarks |
– – – |
2017-01-20 |
4 |
AS |
$33.24 |
$76,208 |
D/D |
(2,293) |
29,407 |
|
- |
|
| Bryce Richard Paul |
SR VP, CLINICAL RESEARCH & DEV |
• – – |
2017-01-20 |
4 |
AS |
$33.24 |
$76,208 |
D/D |
(2,293) |
29,237 |
|
- |
|
| Auerbach Alan H |
PRESIDENT AND CEO |
• • • |
2017-01-20 |
4 |
AS |
$33.24 |
$339,064 |
D/D |
(10,202) |
4,179,798 |
|
- |
|
| Lo Steven |
Chief Commercial Officer |
• – – |
2016-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
31,500 |
31,500 |
|
- |
|
| Charnas Robert |
See Remarks |
– – – |
2016-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
31,500 |
31,700 |
|
- |
|
| Eyler Charles R |
SEE REMARKS |
• – – |
2016-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
10,500 |
|
- |
|
| Bryce Richard Paul |
SR VP, CLINICAL RESEARCH & DEV |
• – – |
2016-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
31,500 |
31,530 |
|
- |
|
| Auerbach Alan H |
PRESIDENT AND CEO |
• • • |
2016-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
4,190,000 |
|
- |
|
| Charnas Robert |
|
– – – |
2016-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
200 |
|
- |
|
| Zavrl Frank |
Director |
– • – |
2015-09-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
909,076 |
|
- |
|
| Bryce Richard Paul |
SR VP, CLINICAL RESEARCH & DEV |
• – – |
2015-07-06 |
4 |
AS |
$110.03 |
$330,084 |
D/D |
(3,000) |
30 |
|
- |
|
| Bryce Richard Paul |
SR VP, CLINICAL RESEARCH & DEV |
• – – |
2015-07-06 |
4 |
OE |
$11.30 |
$33,900 |
D/D |
3,000 |
3,030 |
|
- |
|
| Bryce Richard Paul |
SR VP, CLINICAL RESEARCH & DEV |
• – – |
2014-04-11 |
4 |
B |
$82.49 |
$2,310 |
D/D |
28 |
30 |
2.66 |
- |
|
| Bryce Richard Paul |
SR VP, CLINICAL RESEARCH & DEV |
• – – |
2014-04-09 |
4 |
B |
$87.35 |
$175 |
D/D |
2 |
2 |
2.66 |
- |
|
300 Records found
|
|
Page 12 of 12 |
|
|
0.02 (0.42%) 
